PDF(Pubmed)
Abstract：
UNASSIGNED: Immunotherapy targeting factors related to immune imbalance has been widely employed for RA treatment. This study aimed to evaluate the efficacy and safety of low-dose interleukin (IL)-2 combined with tocilizumab (TCZ), a biologics targeting IL-6, in RA patients.
UNASSIGNED: Fifty adults with active RA who met the criteria with complete clinical data were recruited, and divided into three groups: control group (n=15), IL-2 group (n=26), and IL-2+TCZ group (n=9). In addition to basic treatment, participants in the IL-2 group received IL-2 (0.5 MIU/day), while participants in the IL-2+TCZ group received IL-2 (0.5 MIU/day) along with one dose of TCZ (8 mg/kg, maximum dose: 800 mg). All subjects underwent condition assessment, laboratory indicators and safety indicators detection, and records before treatment and one week after treatment.
UNASSIGNED: Compared with the baseline, all three groups showed significant improvement in disease conditions, as evidenced by significantly reduced disease activity indicators. The low-dose IL-2 and combination treatment groups demonstrated a violent proliferation of Tregs, while the absolute number of Th1, Th2, and Th17 cells in the latter group showed a decreasing trend. The decrease in the Th17/Treg ratio was more pronounced in the IL-2+TCZ groups. No significant adverse reactions were observed in any of the patients.
UNASSIGNED: Exogenous low doses of IL-2 combined TCZ were found to be safe and effective in reducing effector T cells and appropriately increasing Treg levels in RA patients with high effector T cell levels. This approach helps regulate immune homeostasis and contributes to the prevention of disease deterioration.
UNASSIGNED: https://www.chictr.org.cn/showprojEN.html?proj=13909, identifier ChiCTR-INR-16009546.
UNASSIGNED: Fifty adults with active RA who met the criteria with complete clinical data were recruited, and divided into three groups: control group (n=15), IL-2 group (n=26), and IL-2+TCZ group (n=9). In addition to basic treatment, participants in the IL-2 group received IL-2 (0.5 MIU/day), while participants in the IL-2+TCZ group received IL-2 (0.5 MIU/day) along with one dose of TCZ (8 mg/kg, maximum dose: 800 mg). All subjects underwent condition assessment, laboratory indicators and safety indicators detection, and records before treatment and one week after treatment.
UNASSIGNED: Compared with the baseline, all three groups showed significant improvement in disease conditions, as evidenced by significantly reduced disease activity indicators. The low-dose IL-2 and combination treatment groups demonstrated a violent proliferation of Tregs, while the absolute number of Th1, Th2, and Th17 cells in the latter group showed a decreasing trend. The decrease in the Th17/Treg ratio was more pronounced in the IL-2+TCZ groups. No significant adverse reactions were observed in any of the patients.
UNASSIGNED: Exogenous low doses of IL-2 combined TCZ were found to be safe and effective in reducing effector T cells and appropriately increasing Treg levels in RA patients with high effector T cell levels. This approach helps regulate immune homeostasis and contributes to the prevention of disease deterioration.
UNASSIGNED: https://www.chictr.org.cn/showprojEN.html?proj=13909, identifier ChiCTR-INR-16009546.
摘要：
■与免疫失衡相关的免疫治疗靶向因子已广泛用于RA治疗。本研究旨在评价低剂量白细胞介素（IL）-2联合托珠单抗（TCZ）的疗效和安全性。RA患者中靶向IL-6的生物制剂。
■招募了50名具有完整临床数据且符合标准的活动性RA成年人，分为三组：对照组（n=15），IL-2组（n=26），和IL-2+TCZ组(n=9)。除了基础治疗,IL-2组的参与者接受IL-2（0.5MIU/天），而IL-2+TCZ组的参与者接受IL-2（0.5MIU/天）以及一剂TCZ（8mg/kg，最大剂量：800毫克）。所有受试者都接受了病情评估，实验室指标和安全指标检测，并记录治疗前和治疗后1周。
■与基线相比，所有三组的疾病状况都有显著改善，如显著降低的疾病活动指标所证明。低剂量IL-2和联合治疗组表现出Tregs的剧烈增殖，而后者的Th1、Th2和Th17细胞的绝对数量呈减少趋势。在IL-2+TCZ组中,Th17/Treg比率的降低更显著。所有患者均未出现明显不良反应。
■在高效应T细胞水平的RA患者中，发现外源性低剂量IL-2联合TCZ在减少效应T细胞和适当增加Treg水平方面是安全有效的。这种方法有助于调节免疫稳态，并有助于预防疾病恶化。
■https://www.chictr.org.cn/showprojEN.html?proj=13909，标识符ChiCTR-INR-16009546。
■招募了50名具有完整临床数据且符合标准的活动性RA成年人，分为三组：对照组（n=15），IL-2组（n=26），和IL-2+TCZ组(n=9)。除了基础治疗,IL-2组的参与者接受IL-2（0.5MIU/天），而IL-2+TCZ组的参与者接受IL-2（0.5MIU/天）以及一剂TCZ（8mg/kg，最大剂量：800毫克）。所有受试者都接受了病情评估，实验室指标和安全指标检测，并记录治疗前和治疗后1周。
■与基线相比，所有三组的疾病状况都有显著改善，如显著降低的疾病活动指标所证明。低剂量IL-2和联合治疗组表现出Tregs的剧烈增殖，而后者的Th1、Th2和Th17细胞的绝对数量呈减少趋势。在IL-2+TCZ组中,Th17/Treg比率的降低更显著。所有患者均未出现明显不良反应。
■在高效应T细胞水平的RA患者中，发现外源性低剂量IL-2联合TCZ在减少效应T细胞和适当增加Treg水平方面是安全有效的。这种方法有助于调节免疫稳态，并有助于预防疾病恶化。
■https://www.chictr.org.cn/showprojEN.html?proj=13909，标识符ChiCTR-INR-16009546。
